H.C. Wainwright analyst Ed Arce initiated coverage of Aligos Therapeutics with a Buy rating and $75 price target. The company’s two “de-risked assets” in large market opportunities are “completely overlooked by the Street,” the analyst tells investors in a research note. The firm views current levels as an “excellent entry point” to add or establish a position in Aligos.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS: